Oral anticoagulation for adults with atrial fibrillation or venous thromboembolism

Area of Science:

• Pharmacology
• Cardiology
• Hematology

Background:

• Direct-acting oral anticoagulants (DOACs) represent a significant advancement in anticoagulant therapy.
• Current DOACs include apixaban, rivaroxaban, and dabigatran, offering alternatives to warfarin.
• Specific patient populations, such as those with valvular AF, mechanical heart valves, or cancer-associated VTE, have distinct first-line treatment recommendations.

Purpose of the Study:

• To outline the appropriate use of DOACs in patients with non-valvular atrial fibrillation (AF) and venous thromboembolism (VTE).
• To highlight specific clinical scenarios where DOACs are preferred or require dose adjustments.
• To discuss the role of laboratory monitoring in DOAC therapy.

Main Methods:

• Review of current clinical guidelines and evidence regarding DOAC use.
• Identification of patient groups and conditions for which DOACs are indicated.
• Analysis of factors influencing DOAC dosing and the necessity of laboratory monitoring.

Main Results:

• DOACs are suitable for most patients with non-valvular AF or VTE.
• Warfarin remains first-line for valvular AF with mechanical heart valves or rheumatic mitral stenosis.
• Apixaban and rivaroxaban are preferred for cancer-associated VTE and in obese patients (BMI >35 kg/m² or weight >120 kg).
• Dose adjustments for DOACs are necessary in moderate kidney impairment.
• Routine laboratory monitoring of DOACs is not typically required but beneficial in specific situations like emergencies or suspected inadequate/excessive anticoagulation.

Conclusions:

• DOACs offer a broad therapeutic window for AF and VTE management.
• Individualized treatment decisions are crucial, considering patient-specific factors like valvular status, malignancy, obesity, and renal function.
• While routine monitoring is not standard, targeted laboratory assessment can aid in managing complex clinical scenarios and potential complications.